

PATENT 1645

Case Docket No. GNE.1618P2C31

Date: September 27, 2002

In re application of : Ashkenazi et al.
App. No. : 09/905,088
Filed : July 12, 2001
For : SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND
NUCLEIC ACIDS
ENCODING THE SAME
Examiner : Unknown
Art Unit : 1645

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: United States Patent and Trademark Office, PO Box 2327, Arlington VA 22202, on

September 27, 2002

(Date)


Ginger R. Dreger, Reg. No. 33,055

TECH CENTER 1600/2900

OCT 07 2002


RECEIVED

United States Patent and Trademark Office
PO Box 2327
Arlington VA 22202

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with two (2) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Ginger R. Dreger
Registration No. 33,055
Attorney of Record

GNE.1618P2C31



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ashkenazi et al.) Group Art Unit 1645
App. No. : 09/905,088)
Filed : July 12 2001)
For : SECRETED AND)
TRANSMEMBRANE)
POLYPEPTIDES AND)
NUCLEIC ACIDS ENCODING)
THE SAME)
Examiner : Unknown)

RECEIVED

OCT 07 2002

TECH CENTER 1600/2900

#13
P.O.
10/10/02

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
PO Box 2327
Arlington, VA 22202

Dear Sir:


Enclosed is form PTO-1449 listing 2 references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: September 27, 2002

By:


Ginger R. Dreger
Registration No. 33,055
Attorney of Record
2040 Main Street, 14th Floor
Irvine, CA 92614
(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
GNE.1618P2C31

APPLICATION NO. 09/905,088

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Ashkenazi et al.FILING DATE
July 12, 2001GROUP
1645

RECEIVED

OCT 07 2002

TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
1. <input checked="" type="checkbox"/>	Taguchi et al., "Molecular cloning of novel leucine-rich repeat proteins and their expression in the developing mouse nervous system," <i>Molecular Brain Research</i> , 35(1-2): 31-40 (1996).
2. <input checked="" type="checkbox"/>	Almeida et al., "GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas," <i>Oncogene</i> , 16(23): 2997-3002 (1998)

W:\DOCS\BGY\BGY-2709.DOC
091902

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	